^
    Back
    Association details:
    Biomarker:LDH-L
    Cancer:Uveal Melanoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Jingzhuda (entinostat) (HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Nat Commun
    Title:

    The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

    Published date:
    08/27/2021
    Excerpt:
    We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab in patients with metastatic uveal melanoma (UM)....Longer survival also correlated with low baseline ctDNA levels or LDH.
    DOI:
    10.1038/s41467-021-25332-w
    Trial ID:
    PEMDAC